// App-Quantinova.ai

: Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.

Researchers

Presenter

  • Ning Li

Principal Investigators

  • Wen-Ying Deng

  • Yi-Jie Ma

  • Liang-Yu Bie

  • Chi Zhang

  • Chen Wei

  • Suxia Luo

Medical Centers

  • Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

  • Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Capecitabine and oxaliplatin

  • anlotinib

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04891900

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved